Category Archives: Business and Investments

Latest From Business and Investments

ARPA-E Innovation Summit Comes to Washington, DC.

arpa-e-logo

The U.S. Department of Energy’s ARPA-E Innovation Summit is scheduled for February 24-26, 2014 in Washington, DC. The Advanced Research Projects Agency-Energy (ARPA-E) funds transformational projects that create entirely new ways to generate, store, and use energy. Since September 2013, ARPA-E has announced almost $125 million in funding for new projects aimed at finding innovative ways to lower the cost and improve the efficiency of energy technologies. “We’re investing in the best people, the best Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Testifies Before The Michigan Bioscience Caucus

admin-ajax

BIO‘s Senior Policy Consultant, Peter Pellerito, recently testified before the Michigan Legislature’s Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry. As part of the testimony, Pellerito discussed state legislative capital formation and R&D legislative strategies that support technology transfer and industry growth within state borders. Read the transcript of the testimony here.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

BIO CEO: Five Prime Therapeutics Company Snapshot

fiveprime

Five Prime Therapeutics is another company that will be presenting at next week’s BIO CEO & Investor Conference. They will be among 20 other presenters at the event who debuted an IPO in the last two years. Read below to learn more about their work, and what to expect from them at the event. Company Snapshot What is your company’s lead product or technology? Five Prime focuses on discovering and developing novel protein therapeutics for Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

tetraphase

The BIO CEO & Investor Conference is now just a week away, and buzz for the event has never been greater. Tomorrow, Inside BIO is hosting its first ever twitter chat to discuss the annual buyside survey, which has been getting great responses from the investor community. Presentation spots are still sold out as well, and we’re continuing to highlight those companies slated to present. One such company is Tetraphase Pharmaceuticals, who went public this Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,